The 36-Patient Acne Laser Pilot Published in 2026: What the Findings Mean for Adults With Persistent Acne

The 36-patient pilot tested IPL, PDL, and Q-switched 1064-nm Nd:YAG laser for moderate-to-severe inflammatory acne. All three groups improved, with no clear winner, so adults with persistent red, tender breakouts should view devices as possible add-ons rather than replacements. Inflammatory acne means red papules, pustules, and tender nodules, not just blackheads.

IPL means intense pulsed light and PDL means pulsed dye laser. The U.S. National Library of Medicine PubMed trial record reports lesion counts and severity scores fell significantly within each device group.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What did the pilot test?
Did one device work better?
Did daily life improve?
Why has routine care not changed?
What should adults ask next?

What did the pilot test?

The trial enrolled 36 patients with moderate-to-severe inflammatory acne. Researchers assigned 12 patients each to IPL, PDL, or Q-switched 1064-nm Nd:YAG laser. Each group received a course of treatment with lesion counts and severity scores tracked over sessions.

The design was small and direct. It compared three active devices without a no-treatment group. That structure can show change during care, but it cannot separate device effects from time, skin care, or placebo response.

Did one device work better?

No. Lesion counts and severity scores did not differ significantly between the three groups at any session. The U.S.

National Library of Medicine between-group comparison reports P-values from 0.06 to 0.92. For a reader choosing care, that tie matters more than the improvement curve. The pilot gives no reason to seek one of these three devices over another for effectiveness alone. Practical issues like sessions, cost, pain, redness, and dark-spot risk become the real comparison points.

Did daily life improve?

Yes, in the short term. Acne-related disability fell significantly from baseline to two weeks after the final treatment across groups. The measure was the Cardiff Acne Disability Index, a short questionnaire about embarrassment, social interference, and daily bother.

That outcome matters because persistent acne often lasts past the teen years. A British Journal of Dermatology epidemiology review via Oxford Academic abstract found acne persists into the 20s in about 64% and into the 30s in about 43% of affected individuals. Less bother for two weeks is welcome, but it does not prove lasting clearance.

Why has routine care not changed?

Size and follow-up are the main limits. About 12 patients per arm is too small to detect modest differences or rare pigmentation events. Disability follow-up only two weeks after treatment cannot establish durability, recurrence, or scarring effects.

Broader guidance remains cautious for the same reason. American Academy of Dermatology guidance reported via MedicalXpress report concluded in 2024 that evidence was insufficient to recommend lasers and light-based devices for routine acne care. One small pilot does not overturn that position.

What should adults ask next?

Keep proven care as the base. Continue topical retinoids, benzoyl peroxide, or prescribed antibiotics exactly as directed unless your dermatologist changes them.

Treat a device as a possible adjunct, not a substitute. Use one visit to get concrete answers: Bring a list of current topicals, past antibiotics, and pigmentation history to that visit.

Do my lesions and skin tone make me a reasonable candidate?
How many sessions, what pain and redness, and what hyperpigmentation risk apply to me?
What total cost, aftercare, sun protection, and follow-up plan should I expect?